Roche (VTX:ROG) has been assigned a CHF 325 price target by equities researchers at Goldman Sachs Group in a report released on Tuesday. The brokerage currently has a “buy” rating on the healthcare company’s stock. Goldman Sachs Group’s target price indicates a potential upside of 48.44% from the company’s previous close.
A number of other research firms have also weighed in on ROG. set a CHF 203 price objective on shares of Roche and gave the company a “sell” rating in a research note on Friday, October 20th. Baader Bank set a CHF 256 price objective on shares of Roche and gave the company a “buy” rating in a research note on Tuesday, November 21st. Barclays set a CHF 305 price objective on shares of Roche and gave the company a “buy” rating in a research note on Wednesday, December 27th. Berenberg Bank set a CHF 260 price objective on shares of Roche and gave the company a “neutral” rating in a research note on Tuesday, October 24th. Finally, DZ Bank set a CHF 270 price target on shares of Roche and gave the company a “buy” rating in a research report on Friday, February 2nd. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of CHF 257.20.
Roche (ROG) opened at CHF 218.95 on Tuesday. Roche has a 12 month low of CHF 214.30 and a 12 month high of CHF 273. The firm has a market cap of $189,580.00 and a price-to-earnings ratio of 21.81.
ILLEGAL ACTIVITY NOTICE: This news story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/13/goldman-sachs-group-analysts-give-roche-rog-a-chf-325-price-target.html.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.